As expected, TNBS administration induced a strong colitis resulting in significant body weight loss (by 16.3 ± 1.33%, Figure 4A), high macroscopic (Wallace score of 7 ± 0.25; p < 0.0001; Figure 4B) and histological (Ameho score of 6.6 ± 0.2; Figure 4C,D) scores of inflammation, correlated with a significant increase in the plasmatic level of IL-6 (795 pg/mL; p < 0.05; Figure 5A) and of the expression of all the proinflammatory genes tested (Figure 5C; p < 0.05 to 0.0001). Here, IL6 is linked to colitis.